MDxHealth, the maker of prostate cancer diagnostics, just acquired Dutch liquid biopsy company NovioGendix for $8.8 million. With the new urine-based test, slated for release next year under the name SelectMDx, it aims to reduce unnecessary biopsies for prostate cancer.
Molecular diagnostics company MDxHealth and partner NovioGendix have been awarded a $1.1 million grant that will be applied toward research and development of a new bladder cancer diagnostic. Belgium-based MDxHealth (BRU:MDXH), which has its U.S. headquarters in Durham, North Carolina, develops companion diagnostics for cancer treatments. The grant to MDxHealth and Dutch molecular diagnostics firm […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.